Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib long-term safety in SSc-ILD (extension of SENSCIS)
CTR20180930Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), sponsored by Boehringer Ingelheim. Started Jul 2018; status: completed.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on CTR20180930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180930.